The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback